TY  - GEN
AU  - Xue,Zheng
AU  - Vis,Daniel J
AU  - Bruna,Alejandra
AU  - Sustic,Tonci
AU  - van Wageningen,Sake
AU  - Batra,Ankita Sati
AU  - Rueda,Oscar M
AU  - Bosdriesz,Evert
AU  - Caldas,Carlos
AU  - Wessels,Lodewyk F A
AU  - Bernards,René
TI  - MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models
SN  - 1748-7838
PY  - 2019///1008
KW  - Animals
KW  - Benzimidazoles
KW  - pharmacology
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Cell Line, Tumor
KW  - Colonic Neoplasms
KW  - Drug Resistance, Neoplasm
KW  - genetics
KW  - Female
KW  - Heterografts
KW  - Humans
KW  - Loss of Function Mutation
KW  - MAP Kinase Kinase 4
KW  - antagonists & inhibitors
KW  - MAP Kinase Kinase Kinase 1
KW  - MAP Kinase Signaling System
KW  - drug effects
KW  - Male
KW  - Mice, Inbred BALB C
KW  - Mice, Nude
KW  - Mitogen-Activated Protein Kinase Kinases
KW  - Prostatic Neoplasms
KW  - Protein Kinase Inhibitors
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/s41422-018-0044-4
ER  -